Results 81 to 90 of about 5,988 (201)
This 25‐year national analysis reveals a major shift in atrial fibrillation‐related mortality, driven by rapidly rising rates of heart failure and stroke‐free dementia. These trends underscore the urgent need to expand management beyond traditional stroke prevention to prioritize comprehensive heart failure care and cognitive health.
Jacqueline S. Dickey +11 more
wiley +1 more source
Viscoelastic monitoring of direct oral anticoagulants (DOAC): Viscoeslastic monitoring of DOAC
The management of procedures at risk of major or critical bleeding in patients treated with direct oral anticoagulants (DOAC) is challenging, making urgent monitoring to detect and quantify residual effects, optimal for accurate clinical decision making.
Mora, Lidia +2 more
openaire +1 more source
ABSTRACT Background Direct oral anticoagulants (DOACs) are prescribed using fixed dosing regimens, despite limited evidence on their pharmacokinetic behavior in nursing home residents. Participants and Setting One hundred nursing home residents are receiving apixaban, rivaroxaban, dabigatran, or edoxaban in multiple long‐term care facilities in the ...
Irme S. Franssen +11 more
wiley +1 more source
Background: For patients with atrial fibrillation and a prior stroke or transient ischemic attack (TIA), the risk-benefit of direct oral anticoagulants (DOACs) compared to alternative treatment approaches has not been firmly established.
Kuan-Hsin Lee +4 more
doaj +1 more source
ABSTRACT Background Direct oral anticoagulants (DOACs) are the first‐line therapy for stroke prevention in non‐valvular atrial fibrillation and venous thromboembolism. While evidence supports their continuation during routine dental procedures such as tooth extractions, data on oral soft tissue biopsies remain limited.
Rossana Izzetti +3 more
wiley +1 more source
Warfarin versus DOACs in the prevention of thromboembolic stroke in patients with Afib.
Purpose: Preventing thromboembolic (TE) events “such as stroke” is an important part of managing patients with non-valvular atrial fibrillation (Afib). Over the last 50 years, oral anticoagulant treatment with the Vitamin K Antagonist (VKA) warfarin has ...
Szabon, Allen
core +1 more source
Background The efficacy and safety of the direct oral anticoagulants (DOACs) in fragile patients (age ≥ 75 years and/or creatinine clearance levels ≤ 50 mL/min and/or body weight ≤ 50kg) with venous thromboembolism (VTE) has not been evaluated.
Juan J. López-Núñez +9 more
doaj +1 more source
Management of Left Atrial Appendage Thrombi and Spontaneous Echo Contrast
ABSTRACT Background To analyze the efficacy and safety of various anticoagulation strategies/regimen used for managing thrombus or spontaneous echo contrast in the left atrial appendage. Methods Thrombus or spontaneous echo contrast in the left atrial appendage was detected via transesophageal echocardiography in 83 patients, most often during a stroke
Timnou Bekouti Jean +10 more
wiley +1 more source
ABSTRACT Background Left atrial appendage occlusion (LAAO) has emerged as a non‐pharmacological alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). Following the publication of recent CHAMPION‐AF and CLOSURE‐AF trials, an updated synthesis of evidence is warranted to clarify the long‐term ...
Ahmed Nazmy +11 more
wiley +1 more source
Comparative efficacy and safety of warfarin and direct oral anticoagulants in patients with end-stage kidney disease and atrial fibrillation [PDF]
Background/Aims Patients with atrial fibrillation (AF) and end-stage kidney disease (ESKD) require careful anticoagulation because thrombotic and bleeding risks are both elevated.
Yujin Yang +4 more
doaj +1 more source

